Key statistics dashboard for Alaunos Therapeutics, Inc. (TCRT). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies. Their pipeline includes a TCR Library, currently undergoing Phase I/II clinical trials, which comprises ten T-cell receptors designed to target mutated KRAS, TP53, and EGFR in various cancers such as non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
Stock Data
| Price | $1.28 |
| Market Cap | $3M |
| Beta | -1.13 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.68 |
| Price / Book | 4.98 |
| P/S | 1086.75 |
| P/FCF | -1.15 |
Profitability
| Gross Margin | -28133.33% |
| EBIT Margin | -133666.67% |
| EBITDA Margin | -132866.67% |
| Operating Margin | -135266.67% |
| Net Margin | -133666.67% |
Financial Health
| Current Ratio | 0.77 |
| Quick Ratio | 0.77 |
| Cash Ratio | 0.14 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | 0.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -436.02 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.27 |
| Cash per share | 0.05 |
| FCF per share | -1.16 |
| Tangible Book Value per share | 0.27 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 1 |
| Hold | 8 |
| Sell | 1 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.00 |
Related companies: ADXN · AIM · CYCN · IBO · KTTA · PLRZ · QNRX
Explore sector: Healthcare · Biotechnology
More sections of TCRT: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks